(Q39502937)

12 September 2017

title

Treatment options for hepatitis delta virus infection (English)

1 reference

12 September 2017

main subject

hepatitis delta virus

object named as

hepatitis delta virus

1 reference

2

Michael P Manns

1 reference

12 September 2017

3

Heiner Wedemeyer

1 reference

12 September 2017

Benjamin Heidrich

1

1 reference

12 September 2017

publication date

1 February 2013

1 reference

Current infectious disease reports

12 September 2017

published in

1 reference

12 September 2017

volume

15

1 reference

12 September 2017

issue

1

1 reference

12 September 2017

page(s)

31-38

1 reference

Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Epidemiological aspects of hepatitis B and D virus infection in the northern region of Amazonas, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Hepatitis D virus infection--not a vanishing disease in Europe!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Virological and clinical characteristics of delta hepatitis in Central Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

The increasing prevalence of hepatitis delta virus (HDV) infection in South London

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Delta hepatitis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Chronic hepatitis D: a vanishing Disease? An Italian multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

21 January 2018

Hepatitis delta virus

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Geographic distribution and genetic variability of hepatitis delta virus genotype I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Intrafamilial transmission of hepatitis delta virus: molecular evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Outcome of chronic delta hepatitis in Italy: a long-term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Famciclovir treatment of chronic delta hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Entecavir treatment of chronic hepatitis D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Hepatitis delta and HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Hepatitis delta in Europe: Vanishing or refreshing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0307-Z

Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis

21 January 2018

1 reference

12 December 2020

Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues

1 reference

12 December 2020

Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis

1 reference

12 December 2020

Two-year interferon therapy with or without ribavirin in chronic delta hepatitis

1 reference

12 December 2020

Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy

1 reference

12 December 2020

Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis

1 reference

12 December 2020

HDV genotypes in the Western Brazilian Amazon region: A preliminary report.

1 reference

12 December 2020

An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador

1 reference

12 December 2020

Hepatitis delta virus

1 reference

12 December 2020

Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?

1 reference

12 December 2020

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation.

1 reference

12 December 2020

Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients

1 reference

12 December 2020

A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta

1 reference

12 December 2020

HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome

1 reference

12 December 2020

Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis.

1 reference

12 December 2020

Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains.

1 reference

12 December 2020

Treatment of chronic hepatitis D with interferon alfa-2a

1 reference

12 December 2020

10.1007/S11908-012-0307-Z

Identifiers

DOI

1 reference

release_zmaghmu6krb3phngde5nb4ddbm

12 September 2017

Fatcat ID

0 references

1 reference